Media coverage about G1 THERAPEUTICS (NASDAQ:GTHX) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. G1 THERAPEUTICS earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.6896901510362 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

GTHX has been the subject of a number of research analyst reports. Cowen and Company reissued a “buy” rating on shares of G1 THERAPEUTICS in a report on Wednesday, August 9th. Zacks Investment Research lowered G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $29.75.

Shares of G1 THERAPEUTICS (NASDAQ:GTHX) opened at $23.40 on Monday. G1 THERAPEUTICS has a fifty-two week low of $12.04 and a fifty-two week high of $28.67.

G1 THERAPEUTICS (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.48). equities analysts anticipate that G1 THERAPEUTICS will post -2.7 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect G1 THERAPEUTICS (GTHX) Share Price” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at


G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with Analyst Ratings Network's FREE daily email newsletter.